Jimmy Perth (@jimmyperthwa) 's Twitter Profile
Jimmy Perth

@jimmyperthwa

ASX Punter

ID: 1639548768

calendar_today02-08-2013 04:33:37

54 Tweet

131 Followers

1,1K Following

Straight Lines (@straightlinesco) 's Twitter Profile Photo

$PAA/@PharmAust Phase II Dog Trial Achieves Successful Anti-Cancer Outcome One pet dog achieved >60% reduction in tumour burden, with one of its tumours regressing completely Interim Report to be finalised for Elanco with whom PharmAust has an Option Agreement to licence MPL

$PAA/@PharmAust Phase II Dog Trial Achieves Successful Anti-Cancer Outcome

One pet dog achieved >60% reduction in tumour burden, with one of its tumours regressing completely 

Interim Report to be finalised for <a href="/Elanco/">Elanco</a> with whom PharmAust has an Option Agreement to licence MPL
Pisces (@pisceangun) 's Twitter Profile Photo

On SM, blogs or in the press ,anywhere the market is discussed everyone's worried about direction .So many newbies are doing their heads in before they start. The whole world was collapsing 4 months ago now we have the best market ever seen. Nobody knows nothin'. Remember that.

Neurizon (@neurizon_ltd) 's Twitter Profile Photo

Phase IIb Clinical Trial in Pet Dogs with B Cell Lymphoma Identifies Therapeutic Window for Monepantel 🐶🐶🐶 💊💊💊👌👌👌

Phase IIb Clinical Trial in Pet Dogs with B Cell Lymphoma Identifies Therapeutic Window for Monepantel

🐶🐶🐶 💊💊💊👌👌👌
Neurizon (@neurizon_ltd) 's Twitter Profile Photo

PharmAust is pleased to present its Appendix 4C Quarterly Report and Shareholders’ Update for the period ended 31 March 2021 cdn-api.markitdigital.com/apiman-gateway…

PharmAust is pleased to present its Appendix 4C Quarterly Report and Shareholders’ Update for the period ended 31 March 2021

cdn-api.markitdigital.com/apiman-gateway…
WallStreetBets & Co. (@wsbconsensus) 's Twitter Profile Photo

Pharmaust (PAA AT) says Monepantel and Monepantel Sulfone significantly protect against COVID-19 virus mediated cell death and appear to inhibit viral infection by targeting late-stage events